Tom Keane provides a comprehensive review of phase 2 KEYNOTE-057, assessing treatment with pembrolizumab for high-risk, non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette (BCG), current standard of care in this patient population.

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS

Related Content:

Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG: Phase 2 Keynote-057 Trial

Keynote-057 Trial: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy